{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:20:02Z","timestamp":1790274002254,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T00:00:00Z","timestamp":1426291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00262-015-1674-8","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T07:03:38Z","timestamp":1426230218000},"page":"707-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response"],"prefix":"10.1007","volume":"64","author":[{"given":"Naoya","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Izumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoko","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Oji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,14]]},"reference":[{"key":"1674_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466","journal-title":"Lancet Oncol"},{"key":"1674_CR2","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-03-3505","volume":"64","author":"JS Yu","year":"2004","unstructured":"Yu JS, Liu G, Ying H, Yong WH, Black KL et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973\u20134979","journal-title":"Cancer Res"},{"key":"1674_CR3","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-05-0120","volume":"11","author":"R Yamanaka","year":"2005","unstructured":"Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M et al (2005) Clinical evaluation of personalized peptide vaccination for patients with recurrent glioma: results of a clinical phase I\/II trial. Clin Cancer Res 11:4160\u20134167","journal-title":"Clin Cancer Res"},{"key":"1674_CR4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2010.29.7499","volume":"29","author":"M Terasaki","year":"2010","unstructured":"Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T et al (2010) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29:337\u2013344","journal-title":"J Clin Oncol"},{"key":"1674_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1568009023334088","volume":"2","author":"Y Oka","year":"2002","unstructured":"Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H (2002) WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2:45\u201354","journal-title":"Curr Cancer Drug Targets"},{"key":"1674_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0145-2126(99)00037-5","volume":"23","author":"A Tsuboi","year":"1999","unstructured":"Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H et al (1999) Constitutive expression of the Wilms\u2019 tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes the proliferation in response to granulocyte-colony stimulation factor (G-CSF). Leuk Res 23:499\u2013505","journal-title":"Leuk Res"},{"key":"1674_CR7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.4049\/jimmunol.164.4.1873","volume":"164","author":"Y Oka","year":"2000","unstructured":"Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H et al (2000) Cancer immunotherapy targeting Wilms\u2019 tumor gene WT1 product. J Immunol 164:1873\u20131880","journal-title":"J Immunol"},{"key":"1674_CR8","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323\u20135337","journal-title":"Clin Cancer Res"},{"key":"1674_CR9","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1349-7006.2004.tb02188.x","volume":"95","author":"Y Oji","year":"2004","unstructured":"Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S et al (2004) Overexpression of the Wilms\u2019 tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95:822\u2013827","journal-title":"Cancer Sci"},{"key":"1674_CR10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3171\/JNS\/2008\/108\/5\/0963","volume":"108","author":"S Izumoto","year":"2008","unstructured":"Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963\u2013971","journal-title":"J Neurosurg"},{"key":"1674_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1215\/15228517-4-1-39","volume":"4","author":"RB Khan","year":"2002","unstructured":"Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 4:39\u201343","journal-title":"Neuro Oncol"},{"key":"1674_CR12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjc.6603376","volume":"95","author":"AA Brandes","year":"2006","unstructured":"Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V et al (2006) Temozolomide 3\u00a0weeks on and 1\u00a0week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 95:1155\u20131160","journal-title":"Br J Cancer"},{"key":"1674_CR13","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2007.10.7722","volume":"25","author":"A Wick","year":"2007","unstructured":"Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357\u20133361","journal-title":"J Clin Oncol"},{"key":"1674_CR14","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","volume":"28","author":"JR Perry","year":"2010","unstructured":"Perry JR, Belanger K, Mason WP, Fulton D, Kavan P et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051\u20132057","journal-title":"J Clin Oncol"},{"key":"1674_CR15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/neuonc\/nop030","volume":"12","author":"DS Kong","year":"2010","unstructured":"Kong DS, Lee JI, Kim JH, Kim ST, Kim WS et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12:289\u2013296","journal-title":"Neuro Oncol"},{"key":"1674_CR16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11060-010-0423-2","volume":"103","author":"U Abacioglu","year":"2011","unstructured":"Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM et al (2011) Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neuro Oncol 103:585\u2013593","journal-title":"J Neuro Oncol"},{"key":"1674_CR17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/neuonc\/nos295","volume":"15","author":"A Omuro","year":"2013","unstructured":"Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS et al (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15:242\u2013250","journal-title":"Neuro Oncol"},{"key":"1674_CR18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/jjco\/hyp196","volume":"40","author":"Y Chiba","year":"2010","unstructured":"Chiba Y, Hashimoto N, Tsuboi A, Oka Y, Murao A et al (2010) Effects of concomitant temozolomide and radiation therapies on WT1-specific T cells in malignant glioma. Jpn J Clin Oncol 40:395\u2013408","journal-title":"Jpn J Clin Oncol"},{"key":"1674_CR19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"1674_CR20","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/neuonc\/not036","volume":"15","author":"S Momota","year":"2013","unstructured":"Momota S, Narita Y, Miyakita Y, Shibui S (2013) Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 15:1445\u20131450","journal-title":"Neuro Oncol"},{"key":"1674_CR21","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","volume":"101","author":"Y Oka","year":"2004","unstructured":"Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T et al (2004) Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885\u201313890","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1674_CR22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","volume":"51","author":"A Tsuboi","year":"2002","unstructured":"Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T et al (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51:614\u2013620","journal-title":"Cancer Immunol Immunother"},{"key":"1674_CR23","doi-asserted-by":"crossref","first-page":"D913","DOI":"10.1093\/nar\/gkq1128","volume":"39","author":"FF Gonzalez-Galarza","year":"2011","unstructured":"Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Res 39:D913\u2013D919","journal-title":"Nucleic Acid Res"},{"key":"1674_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","volume":"9","author":"T Gorlia","year":"2008","unstructured":"Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3. Lancet Oncol 9:29\u201338","journal-title":"Lancet Oncol"},{"key":"1674_CR25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2010.06.012","volume":"81","author":"J Li","year":"2011","unstructured":"Li J, Wang M, Won M, Shaw EG, Coughlin C et al (2011) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623\u2013630","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1674_CR26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-009-0595-z","volume":"118","author":"D Capper","year":"2009","unstructured":"Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599\u2013601","journal-title":"Acta Neuropathol"},{"key":"1674_CR27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.20.5.1375","volume":"20","author":"R Stupp","year":"2002","unstructured":"Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375\u20131382","journal-title":"J Clin Oncol"},{"key":"1674_CR28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","volume":"22","author":"YB Su","year":"2004","unstructured":"Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD et al (2004) Selective CD4_ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610\u2013616","journal-title":"J Clin Oncol"},{"key":"1674_CR29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10147-011-0294-3","volume":"17","author":"Y Fujimoto","year":"2012","unstructured":"Fujimoto Y, Hashimoto N, Kinoshita M, Miyazaki Y, Tanaka S et al (2012) Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol 17:290\u2013293","journal-title":"Int J Clin Oncol"},{"key":"1674_CR30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.cji.0000211332.68643.98","volume":"30","author":"V Appay","year":"2007","unstructured":"Appay V, Voelter V, Rufer N, Reynard S, Jandus C et al (2007) Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 30:240\u2013250","journal-title":"J Immunother"},{"key":"1674_CR31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1215\/15228517-2007-046","volume":"10","author":"AB Heimberger","year":"2008","unstructured":"Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L et al (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10:98\u2013103","journal-title":"Neuro Oncol"},{"key":"1674_CR32","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.vaccine.2006.12.060","volume":"25","author":"SD Park","year":"2007","unstructured":"Park SD, Kim CH, Kim CK, Park JA, Sohn HJ et al (2007) Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 25:3485\u20133491","journal-title":"Vaccine"},{"key":"1674_CR33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2567.2007.02680.x","volume":"122","author":"CH Kim","year":"2007","unstructured":"Kim CH, Woo SJ, Park JS, Kim HS, Park MY et al (2007) Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122:615\u2013622","journal-title":"Immunology"},{"key":"1674_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-007-0336-x","volume":"57","author":"JT Jordan","year":"2008","unstructured":"Jordan JT, Sun W, Farzana Hussain S, DeAngulo G, Prabhu SS et al (2008) Preferential migration of regulatory T cells mediated by glioma secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123\u2013131","journal-title":"Cancer Immunol Immunother"},{"key":"1674_CR35","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","volume":"58","author":"C Banissi","year":"2009","unstructured":"Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in rat glioma model. Cancer Immunol Immunother 58:1627\u20131634","journal-title":"Cancer Immunol Immunother"},{"key":"1674_CR36","doi-asserted-by":"crossref","first-page":"e59082","DOI":"10.1371\/journal.pone.0059082","volume":"8","author":"LA Sanchez-Perez","year":"2013","unstructured":"Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C et al (2013) Myeloablative temozolomide enhances CD8 T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One 8:e59082","journal-title":"PLoS One"},{"key":"1674_CR37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","volume":"155","author":"RJ North","year":"1982","unstructured":"North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063\u20131074","journal-title":"J Exp Med"},{"key":"1674_CR38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Robbins PF, Yang JC, Yang JC, Hwu P et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850\u2013854","journal-title":"Science"},{"key":"1674_CR39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/neuonc\/noq157","volume":"13","author":"JH Sampson","year":"2011","unstructured":"Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:324\u2013333","journal-title":"Neuro Oncol"},{"key":"1674_CR40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/neuonc\/noq204","volume":"13","author":"CE Fadul","year":"2011","unstructured":"Fadul CE, Fisher JL, Gui J, Hampton TH, C\u00f4t\u00e9 AL et al (2011) Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 13:393\u2013400","journal-title":"Neuro Oncol"},{"key":"1674_CR41","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"28","author":"JH Sampson","year":"2010","unstructured":"Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722\u20134729","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-015-1674-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1674-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:33:26Z","timestamp":1558701206000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-015-1674-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,14]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1007\/s00262-015-1674-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,14]]}}}